EDN1 and melanoma: Of note, HH044 treatment significantly reduced the expression of EDN1, PDGFB, and MMP9, which are known to facilitate melanoma disease progression and serve as druggable targets for pharmacotherapy [48,49,50,51,52,53,54,55].